Abstract
A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 23-24 |
Number of pages | 2 |
Journal | Investigational New Drugs |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - Mar 1992 |
Keywords
- Didemnin-B
- ovarian cancer
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)